Analysis of Major Histocompatibility Complex (MHC) Immunopeptidomes Using Mass Spectrometry.
about
MHC class I-associated peptides derive from selective regions of the human genome.Immunocytokines for cancer treatment: past, present and future.The HLA-A*31:01 allele: influence on carbamazepine treatmentThe Human Leukocyte Antigen (HLA)-B27 Peptidome in Vivo, in Spondyloarthritis-susceptible HLA-B27 Transgenic Rats and the Effect of Erap1 Deletion.Human Leukocyte Antigen (HLA) Peptides Derived from Tumor Antigens Induced by Inhibition of DNA Methylation for Development of Drug-facilitated Immunotherapy.Tools to define the melanoma-associated immunopeptidome.The major histocompatibility complex class I immunopeptidome of extracellular vesicles.I've got algorithm: predicting tumor and autoimmune peptide targets for CD8+ T cells.Approach for Identifying Human Leukocyte Antigen (HLA)-DR Bound Peptides from Scarce Clinical Samples.Advances in mass spectrometry-based cancer research and analysis: from cancer proteomics to clinical diagnostics.GibbsCluster: unsupervised clustering and alignment of peptide sequences.Current tools for predicting cancer-specific T cell immunity.Building proteomic tool boxes to monitor MHC class I and class II peptides.Mass spectrometry-based proteomic exploration of the human immune system: focus on the inflammasome, global protein secretion, and T cells.The MHC Class II Immunopeptidome of Lymph Nodes in Health and in Chemically Induced Colitis.Immunoproteasome deficiency in non-small cell lung cancer and its relevance to immunotherapy.The SysteMHC Atlas project.Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry.TBVAC2020: Advancing Tuberculosis Vaccines from Discovery to Clinical DevelopmentProfiling MHC II immunopeptidome of blood-stage malaria reveals that cDC1 control the functionality of parasite-specific CD4 T cells.An automated benchmarking platform for MHC class II binding prediction methods.Informatics for cancer immunotherapy.Immunopharmacogenomics towards personalized cancer immunotherapy targeting neoantigens.Immunogenic HLA-DR-Presented Self-Peptides Identified Directly from Clinical Samples of Synovial Tissue, Synovial Fluid, or Peripheral Blood in Patients with Rheumatoid Arthritis or Lyme Arthritis.Predicted MHC peptide binding promiscuity explains MHC class I 'hotspots' of antigen presentation defined by mass spectrometry eluted ligand data.A Targeted LC-MS Strategy for Low-Abundant HLA Class-I-Presented Peptide Detection Identifies Novel Human Papillomavirus T-Cell Epitopes.Minimal Information About an Immuno-Peptidomics Experiment (MIAIPE).Discrimination Between Human Leukocyte Antigen Class I-Bound and Co-Purified HIV-Derived Peptides in Immunopeptidomics Workflows.A tissue-based draft map of the murine MHC class I immunopeptidomeMapping the tumour human leukocyte antigen (HLA) ligandome by mass spectrometryImmunopeptidomic Profiling of HLA-A2-Positive Triple Negative Breast Cancer Identifies Potential Immunotherapy Target Antigens
P2860
Q37452154-34C75F2C-CFF4-4471-9697-76F9BEE5C8B4Q37560208-8D669114-E73B-45B1-A7F1-56DE12705E66Q37626751-BD11592E-F887-4212-A41F-415AB646683AQ38380973-58F68B9F-1B6C-42C6-81FB-6FF7A551795AQ38390185-866A8221-1DAB-49F0-B330-AB86AFE5647FQ38650013-D392BE16-8893-4F4F-8034-20F7ABCADE62Q38693646-AFEF90E3-D61D-4566-A2AF-71E9E86F4C18Q38731152-EE97605C-391F-4666-BBCE-342113AF96FDQ38756127-FF1358BE-5FC9-4207-86E2-6AF40074FA50Q38816181-7D276002-7993-4DD7-A5B8-7D4AD4EEE514Q38838293-E1AE4444-20C8-4FF9-8C14-6B711B285475Q38953021-EAC6CDC1-1004-40C7-A8AE-A165642C6A60Q39032610-23FD263E-A2F9-4D8F-B910-D294A17D3AF6Q40252565-4F2FC7E4-E99D-4035-83F6-BC02FA44CD37Q41410098-CFDF1FE6-310E-4275-9AD7-2C9B30FFCD04Q41428789-DF5A05DC-3F09-43A3-BCC3-5A957152A46CQ41990341-75787B11-524F-4BFD-B4C7-8FDAC3EB4C5AQ42143897-4330311D-E8F5-455D-8F56-B142172A884FQ42372774-3211C4F4-E481-4585-B3F7-5C0AF99133A6Q45933188-AEB8DC56-B6E1-42B3-ADAB-A472738FE582Q47243904-D8E1EDA4-42B3-4180-94D3-4FA8D9076DDDQ47290509-AD490DBE-482C-4DBF-BEAD-6BA47D48B9D8Q49483662-ECBDB50F-6B56-4100-8F39-BF9BA5E90D9DQ49586408-0769E50B-28B1-4F18-8A5D-6573CE530C7BQ49990705-927F8EFE-A5E4-43A8-AEC4-C5588EE2F00BQ52617409-CB1950F1-3480-471D-8E2D-42DE50D68BFAQ54201155-492E0130-80FC-4AD2-B5A2-7C3605E4A15EQ54204994-C2312F05-31A6-4F91-B374-29A4EEC8AFC0Q57170495-7345F34E-F141-49D0-9AA0-477191D39298Q57178228-A2460662-0D1C-472C-B3FA-EBBB0214761FQ58214193-9FAB2171-F708-41D0-B204-368833A5BF63
P2860
Analysis of Major Histocompatibility Complex (MHC) Immunopeptidomes Using Mass Spectrometry.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Analysis of Major Histocompati ...... domes Using Mass Spectrometry.
@ast
Analysis of Major Histocompati ...... domes Using Mass Spectrometry.
@en
type
label
Analysis of Major Histocompati ...... domes Using Mass Spectrometry.
@ast
Analysis of Major Histocompati ...... domes Using Mass Spectrometry.
@en
prefLabel
Analysis of Major Histocompati ...... domes Using Mass Spectrometry.
@ast
Analysis of Major Histocompati ...... domes Using Mass Spectrometry.
@en
P2093
P2860
P356
P1476
Analysis of Major Histocompati ...... domes Using Mass Spectrometry.
@en
P2093
Ching Chiek Koh
Daniel J Kowalewski
Etienne Caron
Heiko Schuster
Theo Sturm
P2860
P304
P356
10.1074/MCP.M115.052431
P577
2015-12-01T00:00:00Z